Compass Therapeutics Stock

$3.02

7.86% day before yesterday

NYSE, Aug 22, 10:00 pm CET

ISIN

US20454B1044

Symbol

CMPX

Reports

Quarter | Annual

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Compass Therapeutics Stock price

$3.02

-5.48 64.47% 5Y

NYSE, Closing price Fri, Aug 22 2025

+0.22 7.86%

ISIN

US20454B1044

Symbol

CMPX

Reports

Quarter | Annual

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$518.2m

Enterprise Value

$417.2m

Net debt

positive

Cash

$101.0m

Shares outstanding

138.3m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

5.6

Financial Health

Equity Ratio

89.2%

Return on Equity

-39.4%

ROCE

-48.5%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-48.9m | $-81.4m

EBIT

$-49.9m | $-78.1m

Net Income

$-45.4m | $-70.7m

Free Cash Flow

$-45.3m

Growth (TTM | estimate)

Revenue

-100.0% | -100.0%

EBITDA

10.3% | -45.2%

EBIT

9.5% | -37.9%

Net Income

3.9% | -43.2%

Free Cash Flow

-5.5%

EPS

$-0.3

FCF per Share

$-0.3

Short interest

11.1%

Employees

Rev per Employee

$20.0k

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Get Started for Free Today

Compass Therapeutics Stock Analysis

Unlock Scores for Free

??

16 Analysts have issued a Compass Therapeutics forecast:

15x Buy

94%

More details on Analyst Estimates Including Price Targets

16 Analysts have issued a Compass Therapeutics forecast:

Buy

94%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Compass Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	12 12	16% 16% -
- Research and Development Expense	38 38	9% 9% -
EBITDA	-49 -49	10% 10% -
- Depreciation and Amortization	1.01 1.01	58% 58% -
EBIT (Operating Income) EBIT	-50 -50	10% 10% -
Net Profit	-45 -45	4% 4% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Compass Therapeutics Stock News

Positive

Seeking Alpha

●

11 days ago

Compass Therapeutics: Finding Their Way With More Positive Updates In BTC

Compass Therapeutics' pipeline shows promise, especially with tovecimig's positive phase 2 results in biliary tract cancers and upcoming basket study plans. CTX-8371's early signals in NSCLC and TNBC support dose expansion, with detailed phase 1 data expected in Q4 2025. Preclinical candidate CTX-10726 demonstrates potential superiority to competitors, with an IND submission targeted for Q4 2025.

Neutral

GlobeNewsWire

●

11 days ago

Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the pricing of an underwritten public offering of 33,290,000 shares of its common stock at a price to the public of $3.00 per share and pr...

Neutral

GlobeNewsWire

●

12 days ago

Compass Therapeutics Announces Proposed Public Offering

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the launch of an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants t...

More Compass Therapeutics News

Company Profile

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Head office	United States
CEO	Thomas Schuetz
Employees	35
Founded	2014
Website	www.compasstherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now